Clinical trials: Respiratory Distress Syndrom
Glioblastoma, Respiratory Distress Syndrom
NuvOx Expanded Access
NanO₂ is an investigational drug being studied by NuvOx Therapeutics. It has not been approved by the U.S. Food and Drug Administration (FDA) for any use.
- Conditions
- Glioblastoma, Respiratory Distress Syndrom, Ischemic Stroke, Hypoxic Conditions
- Trial name
- NCT07748299
- Testing
- NanO₂
- Sponsor
- NuvOx LLC
Respiratory Distress Syndrom, High Flow Nasal Cannula
Efficacy and Tolerance of High Flow Nasal Cannula for Respiratory Distress Syndrom in Late Preterms (34-36 Weeks)
The main objective of the study is to gather preliminary data on the effectiveness of High Flow Nasal canula (HFNC), provided since the delivery room, for ventilatory support in newborns of 34-36 weeks with moderate respiratory…
- Trial name
- PRIMAIR (NCT02958488)
- Testing
- High Flow Nasal Cannula
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier